Findings

What do systematic reviews say?

4,756 questions · 13,493 findings · 1,305 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,594 · 19.2%GRADE not reported 728 · 5.4%Very low 2,868 · 21.3%Low 3,777 · 28%Moderate 2,620 · 19.4%High 906 · 6.7%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Angiotensin‐converting enzyme inhibitors vs placebo

QoL · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Phosphodiesterase inhibitors vs placebo

QoL · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Phosphodiesterase inhibitors vs placebo

Adverse events · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 138 participants
GRADE not reported

Phosphodiesterase inhibitors vs placebo

RCS · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 79 participants
Low

Angiotensin‐converting enzyme inhibitors vs placebo

Adverse events (4 to 6‐week · primary Raynaud's phenomenon

Angiotensin‐converting enzyme inhibitors showed no clear difference in adverse events (4 to 6‐week compared with placebo (low certainty).

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
RR 1.35 [0.67, 2.73]
3 studies · 46 participants
Low

Angiotensin‐converting enzyme inhibitors vs placebo

RCS · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Alpha‐blockers vs placebo

Migraine frequency Number of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
GRADE not reported

Alpha‐blockers vs placebo

Severity of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
GRADE not reported

Alpha‐blockers vs placebo

Duration of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
GRADE not reported

Heliox vs placebo or no treatment

Change in croup score. · children with croup

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 47 participants
Low

Heliox vs placebo or no treatment

Change in respiratory rate at 20 minutes · children with croup

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 47 participants
Low

Heliox vs placebo or no treatment

Change** in heart rate (beats/min) · children with croup

The review found no eligible studies for this question.

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Heliox vs placebo or no treatment

Proportion of children hospitalised · children with croup

Heliox showed no clear difference in proportion of children hospitalised compared with placebo or no treatment (low certainty).

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
OR 0.46 [0.04, 5.41]
1 study · 47 participants
Low

Heliox vs placebo or no treatment

Length of hospital stay · children with croup

The review found no eligible studies for this question.

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Heliox vs placebo or no treatment

Proportion of children intubated · children with croup

The review found no eligible studies for this question.

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Heliox vs placebo or no treatment

Duration of intubation · children with croup

The review found no eligible studies for this question.

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Heliox vs placebo or no treatment

Proportion of children re‐presenting for medical care for ongoing croup symptoms (return to care) · children with croup

Heliox showed no clear difference in proportion of children re‐presenting for medical care for ongoing… compared with placebo or no treatment (low certainty).

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
OR 0.95 [0.12, 7.41]
1 study · 47 participants
Low

Heliox vs placebo or no treatment

Adverse events · children with croup

The review found no eligible studies for this question.

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral methotrexate vs placebo

Primary outcome: complete clinical response (malar/discoid rash) · patients with cutaneous disease in systemic lupus erythematosus

Oral methotrexate may leads to higher primary outcome: complete clinical response (malar/discoid rash) compared with placebo (low certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 3.57 [1.63, 7.84]
1 study · 41 participants
Low

Oral hydroxychloroquine vs placebo

Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus

Oral hydroxychloroquine probably leads to lower secondary outcome: clinical flare compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 0.49 [0.28, 0.89]
1 study · 47 participants
Moderate